Industry accolades underpin the company’s longstanding vision and innovative capabilities, primed to solve the next generation of clinical data challenges.
Bangalore, Karnataka, India: eClinical Solutions, a global provider of digital clinical software and biometrics services, recently announced that it has been recognised as a leader in Everest Group’s inaugural “Life Sciences Clinical Data and Analytics (D&A) Platforms PEAK Matrix® Assessment 2023” report. The proprietary framework assesses 14 clinical D&A platform providers across a range of distinct metrics related to market impact as well as vision and capabilities, of which eClinical Solutions is positioned high in the Leaders quadrant. This placement points to the proven results the elluminate Clinical Data Cloud® delivers as a unified platform to address sponsors’ clinical data and analytics needs, from ingestion through submission.
This Assessment has been licensed to eClinical Solutions.
“When we started eClinical Solutions over a decade ago, we anticipated the industry data problem would continue to get bigger and more complex, and we pioneered a vision to solve these industry-wide challenges with the elluminate Clinical Data Cloud. We are excited to see that not only is this vision now defined as a category, but we are named a leader in this category,” said Raj Indupuri, co-founder and chief executive officer of eClinical Solutions. “We will work hard to build on this position, leveraging our deep, unparalleled expertise to further innovate our platform and service roadmaps, which will enable us to continue delivering the most value to our clients and solve for the data problems of tomorrow, helping them stay ahead of the curve.”
eClinical Solutions’ strengths highlighted within the assessment include:
-
Comprehensiveness of its end-to-end platform, covering clinical data management, analytics, and business intelligence (BI) capabilities;
-
elluminate’s adaptable nature, which allows for seamless data upload, standardisation, and configurable visualisations in reports, all stated areas of client appreciation;
-
Customizability of elluminate, offering an abundance of low-code/No-Code (LCNC) functionalities and drag-and-drop features that allow easy platform navigation and operation for those with limited technical expertise;
-
Use of numerous pre-built connectors for data extraction and reporting dashboards to enable robust data insights for clinical decision-making;
-
Technical and life sciences domain expertise of eClinical Solutions’ team; and
-
Notably short turnaround time from the company’s support team, allowing them to deliver prompt value to their clients.
“There has been a constant rise in clinical data volumes with advancements in innovation and the presence of diverse data sources leveraged in a clinical trial. This has resulted in increased volume and complexity of data, posing challenges in accelerating value generation from data. Unified clinical data and analytics platforms that are specifically tailored to the clinical research industry are capable of transforming data into insights with faster time to value,” said Nisarg Shah, Practice Director at Everest Group. “eClinical Solutions provides a comprehensive, end-to-end platform covering clinical data management, analytics, and business intelligence (BI) capabilities. The platform is customizable, with drag-and-drop features and user-friendly functionalities, making it accessible even to individuals with limited technical expertise. Its technical and life sciences domain expertise has positioned it as a Leader in Life Sciences Clinical Data and Analytics (D&A) Platforms PEAK Matrix Assessment 2023.”
The assessment’s vision and capability evaluation dimension measures companies’ ability to deliver products successfully, which is determined through five subdimensions: vision and strategy, technology capability, flexibility and ease of deployment, engagement and commercial model, and support. eClinical Solutions holds the highest position among leaders in the vision and strategy, flexibility, and ease of deployment subdimensions, and is tied for the highest position in technology capability and support. eClinical Solutions also places high in the three subdimensions of the market impact dimension: market adoption, portfolio mix, and value derived.
Contributing to the company’s recent momentum, eClinical Solutions expanded its artificial intelligence (AI) and machine learning (ML) capabilities within elluminate IQ Review (eIQ Review), enabling data management teams to conduct data review in a more efficient and scalable way. The offering uses AI and ML to rapidly identify anomalous data, which reduces manual efforts and gives data managers and medical reviewers time back to focus on critical data, increasing productivity, improving data quality, and reducing cycle times.
For more information on eClinical Solutions’ innovative elluminate platform, please visit eclinicalsol.com/products.
To read the full Everest Group PEAK Matrix Assessment, please visit eclinicalsol.com/analyst-reports/life-sciences-clinical-data-and-analytics-platforms-peak-matrix-assessment-2023.
Also read: HR Tech Adoption in MSMEs: Challenges & Solutions
Do Follow: CIO News LinkedIn Account | CIO News Facebook | CIO News Youtube | CIO News Twitter
About us:
CIO News, a proprietary of Mercadeo, produces award-winning content and resources for IT leaders across any industry through print articles and recorded video interviews on topics in the technology sector such as Digital Transformation, Artificial Intelligence (AI), Machine Learning (ML), Cloud, Robotics, Cyber-security, Data, Analytics, SOC, SASE, among other technology topics.
